Angiotensin II AT2 receptor subtype: An uprising frontier in cardiovascular disease?

Journal of Hypertension

Volumn 21, Issue 8, 2003, Pages 1429-1443

  Volpe, Massimo ^a,b,f   Musumeci, Beatrice ^a   De Paolis, Paola ^b,c   Savoia, Carmine ^a   Morganti, Alberto ^d,e  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c FATEBENEFRATELLI HOSPITAL   (Italy)

^d Azienda Ospedaliera San Paolo   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiotensin; Angiotensin receptors; Blood pressure; Cardiovascular disease; Cellular growth; Hypertension; Renin angiotensin system; Stroke

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; RENIN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR AUTOREGULATION; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; HORMONAL REGULATION; HUMAN; HYPERTENSION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RECEPTOR BINDING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE RELAXATION;

EID: 0042738775     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200308000-00001     Document Type: Review

References (166)

1. Dzau VJ, Mukoyama M, Pratt RE. Molecular biology of angiotensin receptors: target for drug research? J Hypertens 1994; 12(Suppl 2):S1-S5.
2. de Gasparo M, Catt KJ, Inagami T, Wright JW, Unger T. International Union of Pharmacology. XXIII. The Angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
3. Berk BC, Vekshtein V, Gordon HM, Tsuda T. Angiotensin II-stimulated protein synthesis in cultured vascular smooth muscle cells. Hypertension 1989; 13:305-314.
4. Geisterfer AA, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-856.
5. Naftilan AJ, Pratt RE, Dzau VJ. Induction of platelet-derived growth factor A-chain and c-myc gene expressions by angiotensin II in cultured rat vascular smooth cells. J Clin Invest 1989; 83:1419-1424.
6. Stouffer GA, Owens GK. Angiotensin II induced mitogenesis of spontaneously hypertensive rat-derived cultured smooth muscle cells is dependent on autocrine production of transforming growth factor-β. Circ Res 1992; 70:820-828.
7. Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cells response to angiotensin II. J Clin Invest 1993; 91:2268-2274.
8. 2+ mobilization and protein kinase C activation. J Biol Chem 1989; 264:526-530.
9. Naftilan AJ, Gilliland GK, Elderige CS, Kratt AS. Induction of the protooncogene c-jun by angiotensin II. Mol Cell Biol 1990; 10:5536-5540.
10. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin-angiotensin system in vascular diseases: expanding the field. Hypertension 2001; 38:1382-1387.
11. Raij L. Hypertension and cardiovascular risk factors: role of the angiotensin II-nitric oxide interaction. Hypertension 2001; 37:767-773.
12. Burton J, Poulsen K, Haber E. Competitive inhibitors of renin. Inhibitors effective at physiological pH. Biochemistry 1975; 14:3892-3898.
13. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39:e1-e8.
14. Case DB, Wallace JM, Keim HJ, Sealey JE, Laragh JH. Usefulness and limitations of saralasin, a weak competitive agonist of angiotensin II for evaluating the renin and sodium factors in hypertensive patients. Am J Med 1976; 60:825-836.
15. Atkinson AB, Robertson JI. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 1979; 2:836-839.
16. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325:293-302.
17. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effect of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
18. Biollaz J, Durr J, Brunner HR, Porchet M, Gavras H. Escape from mineralcorticoid excess: the role of angiotensin II. J Clin Endocr Metab 1982; 54:1187-1193.
19. Wolny A, Clozel JP, Rein J, Mory P, Vogt P, Turino M, et al. Functional and biochemical analysis of angiotensin II-forming pathways in the human heart. Circ Res 1997; 80:219-227.
20. Hirakata H, Fouad-Tarazi FM, Bumpus FM, Khosla M, Healy B, Husain A, et al. Angiotensins and the failing heart. Enhanced positive inotropic response to angiotensin I in cardiomyopathic hamster heart in the presence of captopril. Circ Res 1990; 66:891-899.
21. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, et al. Angiotensin II receptors and angiotensin II receptor antagonist. Pharmacol Rev 1993; 45:205-211.
22. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving H, et al. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. The RENAAL Study Investigators N Engl J Med 2001; 345:861-869.
23. Lewis EJ, Hunsicker LG, Clarcke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
24. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
25. Chiu AT, McCall DE, Nguyen TT, Carini DJ, Duncia JV, Wexler RR, et al. Discrimination of angiotensin II receptor subtypes by dithiothreitol. Eur J Pharmacol 1989; 170:117-118.
26. Chang RSL, Lotti VJ. Two distinct angiotensin II receptor binding sites in adrenal revealed by new selective nonpeptide ligands. Mol Pharmacol 1990; 29:347-351.
27. Lin SY, Goodfriend TL. Angiotensin receptors. Am J Physiol 1970; 218:1319-1328.
28. Glossman H, Baukal A, Catt KJ. Angiotensin II receptors in bovine adrenal cortex. Modification of angiotensin II binding by guanyl nucleotides. J Biol Chem 1974; 294:664-666.
29. Glossman H, Baukal A, Catt KJ. Cation dependence of high-affinity angiotensin II binding to adrenal cortex receptors. Science 1974; 185:281-283.
30. Sasaki K, Yamano Y, Bardhan S, Iwai N, Murray JJ, Hasegawa M, et al. Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor. Nature 1991; 351:230-233.
31. Murphy TJ, Alexander RW, Griendling KK, Runge MS, Bernstein KE. Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor. Nature 1991; 351:233-336.
32. Jayadev S, Smith RD, Jagadeesh G, Baukal AJ, Hunyady L, Catt KJ. N-linked glycosylation is required for optimal AT1 a angiotensin receptor expression in COS-7 cells. Endocrinology 1999; 140:2010-2017.
33. Bihoreau C, Monnot C, Davies E, Teutsch B, Bernstein KE, Corvol P, Clauser E. Mutation of Asp74 of the rat angiotensin II receptor confers changes in antagonist affinities and abolishes G-protein coupling. Proc Natl Acad Sci USA 1993; 90:5133-5137.
34. Shirai H, Takahashi K, Katada T, Inagami T. Mapping of G protein coupling sites of the angiotensin II type 1 receptor. Hypertension 1995; 25:726-730.
35. Griendling KK, Rittenhouse SE, Brock TA, Ekstein LS, Gimbrone MA, Alexander RW. Sustained diacylglycerol formation from inositol phospholipids in angiotensin II-stimulated vascular smooth muscle cells. J Biol Chem 1986; 261:5901-5906.
36. Saward L, Zahradka P. Angiotensin II activates phosphatidylinositol 3-kinase in vascular smooth muscle cells. Circ Res 1997; 81:249-257.
37. Berk BC, Corson MA. Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ Res 1997; 80:607-616.
38. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE. Direct stimulation of JAK/STAT pathway by the angiotensin II AT1 receptor. Nature 1995; 375:247-250.
39. de Gasparo M, Levens NR. Pharmacology of angiotensin II receptors in the kidney. Kidney Int 1994; 46:1486-1491.
40. Zhuo J, Alcorn D, Allen AM, Mendelsohn FA. High resolution localization of angiotensin II receptors in rat renal medulla. Kidney Int 1992; 42:1372-1380.
41. Zhuo J, Alcorn D, Harris PJ, Mendelsohn FAO. Localization and properties of angiotensin II receptors in rat kidney. Kidney Int 1993; 44(suppl 42):S40-S46.
42. Navar LG, Inscho EW, Majid SA, Imig JD, Harrison-Bernard LM, Mitchell KD. Paracrine regulation of the renal microcirculation. Physiol Rev 1996; 76:425-536.
43. Gigante B, Rubattu S, Russo R, Porcellini A, Enea I, De Paolis P, et al. Opposite feedback control of renin and aldosterone biosynthesis in the adrenal cortex by angiotensin II AT1-subtype receptors. Hypertension 1997; 30:563-568.
44. Zhuo J, McGregor DP, Mendelsohn FAO. Comparative distribution of angiotensin II receptor subtypes in mammalian adrenal glands. In: Vinson GP, Anderson DC (editors): Adrenal glands, vascular system and hypertension. Melbourne: Journal of Endocrinology; 1996, pp. 53-68.
45. Zhuo J, Allen AM, Yamada H, Sun Y, Mendelsohn FAO. Localization and properties of the angiotensin converting enzyme and angiotensin receptors in the heart. In: Lindpaintner K, Ganten D (editors): The Cardiac Renin-Angiotensin System. New York: Futura; 1994, pp. 63-68.
46. Kobayashi M, Furukawa Y, Chiba S. Positive chronotropic and inotropic effects of angiotensin II in the dog heart. Eur J Pharmacol 1978; 50:17-25.
47. Allen AM, McGregor DP, Chai SY, Donnan GA, Kaczmarczyk S, Richardson K, et al. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol 1992; 32:339-344.
48. Baker KM, Aceto JF. Angiotensin II stimulation of protein synthesis and cell growth in chick heart cells. Am J Physiol 1990; 259:H610-H618.
49. Schorb W, Booz GW, Dostal DE, Conrad KM, Chang KC, Baker KM. Angiotensin II is mitogenic in neonatal rat cardiac fibroblasts. Circ Res 1993; 72:1245-1254.
50. Sadoshima J, Izumo S. Molecular charactenzation of angiotensin II induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor. Circ Res 1993: 73:413-423.
51. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74:1141-1148.
52. Rajagopalan S, Kurz S, Munzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DR. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane-bound NADH/NADPH oxidase activation: contribution to alterations of vasomotor tone. J Clin Invest 1996; 97:1916-1923.
53. Zafari AM, Ushio-Fukai M, Minieri CA, Akers M, Lassegue B, Griendling KK. Arachidonic acid metabolites mediate angiotensin II-induced NADH/NADPH oxidase activity and hypertrophy in vascular smooth muscle cells. Antioxidants Redox Signaling 1999; 1:167-179.
54. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, et al. Expression of a functionally active gp91 phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries. Regulation by angiotensin II. Circ Res 2002; 90:1205-1213.
55. Hsich HJ, Cheng CC, Wu ST, Chiu JJ, Wung BS, Wang DL. Increase of reactive oxygen species (ROS) in endothelial cells by shear flow and involvement of ROS in shear-induced c-fos expression. J Cell Physiol 1998; 175:156-162.
56. Morawietz H, Rueckschloss U, Niemann B, Duerrschmidt N, Galle J, Hakim K, Zerkowski HR. Angiotensin II induces LOX-1, the human endothelial receptor for oxidized low-density lipoprotein. Circulation 1999; 100:899-902.
57. Keidar S, Attias J. Angiotensin II injection into mice increases the uptake of oxidizes LDL by their macrophages via a proteoglycan-mediated pathway. Biochem Biophys Res Commun 1997; 239:63-67.
58. Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 1997; 95:473-478.
59. Touyz RM, He G, El Mabrouk M, Diep Q, Mardigyan V, Schiffrin EL. Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT1 receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats. J Hypertens 2001; 19:553-559.
60. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin 1-receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101:2349-2354.
61. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelia dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
62. Nakajima M, Mukoyama M, Pratt RE, Horuichi M, Dzau VJ. Cloning of cDNA and analysis of the gene for mouse angiotensin II type 2 receptor. Biochem Biophys Res Commun 1993; 197:393-399.
63. Kambayashi Y, Bardhan S, Takahashi K, Tsuzuki S, Inui H, Hamakubo T, Inagami T. Molecular cloning of a novel angiotensin II receptor isoform involved in phosphotyrosine phosphatase inhibition. J Biol Chem 1993; 268:24543-24546.
64. Servant G, Dudley DT, Escher E, Guillemette G. The marked disparity between the sizes of angiotensin type 2 receptors from different tissues is related to different degrees of N-glycosylation. Mol Pharmacol 1994; 45:1112-1118.
65. Koike G, Horiuchi M, Yamada T, Szpirere C, Jacob HJ, Dzau VJ. Human type 2 angiotensin receptor gene cloned, mapped to the X chromosome, and its mRNA is expressed in human lung. Biochem Biophys Res Commun 1994; 203:1842-1850.
66. Hines J, Heerding JN, Fluharty SJ, Yee DK. Identification of angiotensin II type 2 (AT2) receptor domains mediating high-affinity CGP 42112A binding and receptor activation. J Pharmacol Exp Ther 2001; 298:665-673.
67. Bottari SP, Taylor V, King IN, Bogdal Y, Whitebread S, de Gasparo M. Angiotensin II AT2 receptors do not interact with guanine nucleotide binding proteins. Eur J Pharmacol 1991; 207:157-163.
68. Tsutsumi K, Saavedra JM. Heterogeneity of angiotensin II AT2 receptors in the rat brain. Mol Pharmacol 1992; 41:290-297.
69. 3 in the rat fetus. J Biol Chem 1996; 271:15026-15033.
70. + currents involves an inhibitory GTP binding protein. Am J Physiol 1994; 267:C1389-C1397.
71. + current in neurons by an angiotensin II type 2 receptor fragment. Am J Physiol 1995; 268:C278-C282.
72. Hayashida W, Horiuchi M, Dzau VJ. Intracellular third loop domain of angiotensin II type-2 receptor. Role in mediating signal transduction and cellular function. J Biol Chem 1996; 271:21985-21992.
73. Hansen JL, Servant G, Baranski TJ, Fujita T, Iiri T, Haunso S, Sheikh SP. Functional reconstitution of the angiotensin II type 2 receptor and Gi activation. Circ Res 2000; 87:753-759.
74. Tsuzuki S, Matoba T, Eguchi S, Inagami T. Angiotensin II type 2 receptor inhibits cell proliferation and activates tyrosine phosphatase. Hypertension 1996; 28:916-918.
75. Huang XC, Richards EM, Sumners C. Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors. J Biol Chem 1996; 271:15635-15641.
76. Yamada T, Horiuchi M, Dzau VJ. Angiotensin II type 2 receptor mediates programmed cell death. Proc Natl Acad Sci USA 1996; 93:156-160.
77. Horiuchi M, Hayashida W, Kambe T, Yamada T, Dzau VJ. Angiotensin type 2 receptor dephosphorylates Bcl-2 by activating mitogen-activated protein kinase phosphatase-1 and induces apoptosis. J Biol Chem 1997; 272:19022-19026.
78. Bedecs K, Elbaz N, Sutren M, Masson M, Susini C, Strosberg AD, Nahmias C. Angiotensin II type 2 receptors mediate inhibition of mitogen-activated protein kinase cascade and functional activation of SHP-1 tyrosine phosphatase. Biochem J 1997; 325:449-454.
79. Gendron L, Laflamme L, Rivard N, Asselin C, Payet MD, Gallo-Payet N. Signals from the AT2 (angiotensin type 2) receptor of angiotensin II inhibit p21 ras and activate MAPK (mitogen-activated protein kinase) to induce morphological neuronal differentiation in NG108-15 cells. Mol Endocrinol 1999; 13:1615-1626.
80. Stroth U, Blume A, Mielke K, Unger T. Angiotensin AT2 receptor stimulates ERK1 and ERK2 in quiescent but inhibits ERK in NGF-stimulated PC12W cells. Mol Brain Res 2000; 78:175-180.
81. Gendron L, Oligny JF, Payet MD, Gallo-Payet N. Cyclic AMP-independent involvement of Rap1/B-Raf in the angiotensin II AT2 receptor signaling pathway in NG108-15 cells. J Biol Chem 2003; 278:3606-3614.
82. Arima S, Endo Y, Yaoita H, Omata K, Ogawa S, Tsunoda K, et al. Possible role of P-450 metabolite of arachidonic acid in vasodilator mechanism of angiotensin II type 2 receptor in the isolated microperfused rabbit afferent arteriole. J Clin Invest 1997; 100:2816-2823.
83. Dulin NO, Alexander LD, Harwalkar S, Falck JR, Douglas JG. Phospholipase A2-mediated activation of mitogen-activated protein kinase by angiotensin II. Proc Natl Acad Sci USA 1998; 95:8098-8102.
84. Jiao H, Cui XL, Torti M, Chang CH, Alexander LD, Lapetina EG, Douglas JG. Arachidonic acid mediates angiotensin II effects on p21 ras in renal proximal tubular cells via the tyrosine kinase-Shc-Grb2-Sos pathway. Proc Natl Acad Sci USA 1998; 95:7417-7421.
85. Gallinat S, Busche S, Schutze S, Kronke M, Unger T. AT2 receptor stimulation induces generation of ceramides in PC12W cells. FEBS Lett 1999; 443:75-79.
86. Lehtonen JYA, Horiuchi M, Daviet L, Akishita M, Dzau VJ. Activation of the de novo biosynthesis of sphingolipids mediates angiotensin II type 2 receptor-induced apoptosis. J Biol Chem 1999; 274:16901-16906.
87. Buisson B, Bottari SP, de Gasparo M, Gallo-Payet N, Payet MD. The angiotensin AT2 receptor modulates T-type calcium current in non-differentiated NG108 cells. FEBS Lett 1992; 309:161-164.
88. Seyedi N, Xu XB, Nasjiletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995; 26:164-170.
89. 2 production in conscious rats. J Clin Invest 1996; 97:1978-1982.
90. Siragy HM, de Gasparo M, Carey RM. Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35:1074-1077.
91. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRsp by a kinin-dependent mechanism. Hypertension 1998; 31:349-355.
92. Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, et al. Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104:925-935.
93. Grady EF, Sechi LA, Griffin CA, Schambelan M, Kalinyak JE. Expression of AT2 receptors in the developing rat fetus. J Clin Invest 1991; 88:921-933.
94. de Gasparo M, Whitebread S, Kalenga MK, de Hertogh R, Crevoisier P, Thomas K. Down regulation of angiotensin II receptor subtype 2 AT2 in human myometrium during pregnancy. Regul Pept 1994; 53:39-45.
95. Matsubara H, Sugaya T, Murasawa S, Nozawa Y, MoriY, Masaki H, et al. Tissue-specific expression of human angiotensin II AT1 and AT2 receptors and cellular localization of subtype mRNAs in adult human renal cortex using in situ hybridization. Nephron 1998; 80:25-34.
96. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM. Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997; 30:1238-1246.
97. Wang ZQ, Moore AF, Ozono R, Siragy HM, Carey RM. Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. Hypertension 1998; 32:78-83.
98. Nozawa Y, Haruno A, Oda N, Yamasaki Y, Matsuura N, Yamada S, et al. Angiotensin II receptor subtypes in bovine and human ventricular myocardium. J Pharmacol Exp Ther 1994; 270: 566-571.
99. Regitz-Zagroseck V, Friedel N, Heymann A, Bauer P, Neuss M, Rolfs A, et al. Regulation, chamber localization, and subtype distribution of angiotensin II receptors in human hearts. Circulation 1995; 91:1461-1471.
100. Dudley DT, Hubbell SE, Summerfelt ML. Characterization of angiotensin II (AT2) binding sites in R3T3 cells. Regul Pept 1993; 44:199-206.
101. Ichiki T, Kambayashi Y, Inagami T. Multiple growth factors modulate mRNA expression of angiotensin II type-2 receptor in R3T3 cells. Circ Res 1995; 77:1070-1076.
102. Kambayashi Y, Nagata K, Ichiki T, Inagami T. Insulin and insulin-like growth factor-induced expression of angiotensin type 2 receptor in vascular smooth muscle cells. Eur J Biochem 1996; 239:558-565.
103. Horiuchi M, Koike G, Yamada T, Mukoyama M, Nakajima M, Dzau VJ. The growth-dependent expression of angiotensin II type 2 receptor is regulated by transcription factors interferon regulatory factor-1 and -2. J Biol Chem 1995; 270:20225-20230.
104. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 1995; 95:651-657.
105. Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. The angiotensin II type 2(AT2) receptor antagonizes the growth effects of the AT1 receptor:gain-of-function study using gene transfer. Proc Natl Acad Sci USA 1995; 92:10663-10667.
106. Dimmeler S, Rippmann V, Weiland U, Haendeler J, Zeiher AM. Angiotensin II induces apoptosis of human endothelial cells. Protective effect of nitric oxide. Circ Res 1997; 81:970-976.
107. Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. The angiotensin AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. Mol Cell Endocrinol 1996; 122:59-67.
108. Lucius R, Gallinat S, Rosenstiel P, Herdegen T, Sievers J, Unger T. The angiotensin II type 2 (AT2) receptor promotes axonal regeneration in the optic nerve of adult rats. J Exp Med 1998; 188:661-670.
109. Varo N, Iraburu MJ, Varela M, Lopez B, Etayo JC, Diez J. Chronic AT1 blockade stimulates extracellular collagen type 1 degradation and reverse myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35:1197-1202.
110. Tharaux PL, Chatziantoniou C, Fakhouri F, Dussaule JC. Angiotensin II activates collagen I gene through a mechanism involving the MAP/ERK kinase pathway. Hypertension 2000; 36:330-336.
111. Kawano H, Do YS, Kawano Y, Starnes V, Barr M, Law RE, Hsueh WA. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101:1130-1137.
112. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, et al. Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997; 96:3954-3962.
113. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res 1998; 83:1035-1046.
114. Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. Effect of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. J Clin Invest 1997; 99:1926-1935.
115. Yang Z, Bove CM, French BA, Epstein FH, Berr SS, DiMaria JM, et al. Angiotensin II type 2 receptor overexpression preserves left ventricular function after myocardial infarction. Circulation 2002; 106:106-111.
116. Akishita M, Iwai M, Wu L, Zhang L, Ouchi Y, Dzau VJ, Horiuchi M. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 2000; 102: 1684-1689.
117. 2) angiotensin receptor. Proc Natl Acad Sci USA 1999; 96:6506-6510.
118. Kurisu S, Ozono R, Oschima T, Kambe M, Ishida T, Sugino H, et al. Cardiac angiotensin II type 2 receptor activates the kinin/NO system and inhibits fibrosis. Hypertension 2003; 41:99-107.
119. Senbonmatsu T, Ichihara S, Price E, Gaffney FA, Inagami T. Evidence for angiotensin II type 2 receptor-mediated cardiac myocytes enlargement during in vivo pressure overload. J Clin Invest 2000; 106:R25-R29.
120. Ichihara S, Senbonmatsu T, Price E, Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II induced hypertension. Circulation 2001; 104:346-351.
121. Ichihara S, Senbonmatsu T, Price E, Ichiki T, Gaffney A, Inagami T. Targeted deletion of angiotensin II type 2 receptor caused cardiac rupture after acute myocardial infarction. Circulation 2002; 106:2244-2249.
122. Brilla CG, Zhou G, Matsubara L, Weber KL. Collagen metabolism in cultured adult rat cardiac fibroblast: response to angiotensin II and aldosterone. J Mol Cell Cardiol 1994; 26:809-820.
123. Mifune M, Sasamura H, Shimizu-Hirota R, Miyazaki H, Saruta T. Anglotensin II type 2 receptors stimulate collagen synthesis in cultured vascular smooth muscle cells. Hypertension 2000; 36:845-850.
124. Levy BI, Benessiano J, Henrion D, Caputo L, Heymes C, Duriez M, Poitevin P. Chronic blockade of AT2-subtype receptors prevent the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996; 98:418-425.
125. Shimizu-Hirota R, Sasamura H, Mifune M, Nakaya H, Kuroda M, Hayashi M, Saruta T. Regulation of vascular proteoglycan synthesis by angiotensin II type 1 and type 2 receptors. J Am Soc Nephrol 2001; 12:2609-2615.
126. Wu L, Iwai M, Nakagami H, Li Z, Chen R, Suzuki J, Akishita M, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001; 104:2716-2721.
127. Deinum J, Van Gool JM, Kofflard MJ, ten Cate FJ, Danser AH. Angiotensin II type 2 receptors and cardiac hypertrophy in women with hypertrophic cardiomyopathy. Hypertension 2001; 38:1278-1281.
128. Schmieder RE, Erdmann J, Delles C, Jacobi J, Fleck E, Hilgers K, Regitz-Zagrosek V. Effect of angiotensin II type 2-receptor gene (+1675 G/A) on left ventricular structure in humans. J Am Coll Cardiol 2001; 37: 175-182.
129. Kijima K, Matsubara H, Murasawa S, Maruyama K, Ohkubo N, Mori Y, Inada M. Regulation of angiotensin II type 2 receptor gene by the protein kinase C calcium pathway. Hypertension 1996; 27:529-534.
130. De Paolis P, Porcellini A, Gigante B, Giliberti R, Lombardi A, Savoia C, et al. Modulation of AT2 subtype receptor gene activation and expression by AT1 receptor in endothelial cells. J Hypertens 1999; 17:1873-1877.
131. Maeso R, Navarro-Cid J, Munoz-Garcia R, Rodrigo E, Ruilope LM, Lahera V, Cachofeiro V. Losartan reduces phenylephrine constrictor response in aortic rings from spontaneously hypertensive rats. Role of nitric oxide and angiotensin II type 2 receptors. Hypertension 1996; 28:967-972.
132. Jin XQ, Fukuda N, Su JZ, Lai YM, Suzuki R, Tahira Y, et al. AT2 receptor gene transfer downregulates AT1a receptor in vascular smooth muscle cells. Hypertension 2002; 39:1021-1027.
133. Su JZ, Fukuda N, Jin XQ, Suzuki R, Tahira Y, Takagi H. Effect of AT2 receptor on expression of AT1 and TGF-β receptors in VSMCs from SHR. Hypertension 2002; 40:853-858.
134. De Paolis P, Porcellini A, Savoia C, Lombardi A, Gigante B, Frati G, et al. Functional cross-talk between angiotensin II and epidermal growth factor receptors in NIH3T3 fibroblasts. J Hypertens 2002; 20:693-699.
135. 2+ -calmodulin-dependent transactivation of epidermal growth factor receptor. Circ Res 1998; 82:1338-1348.
136. Gigante B, Piras O, Savoia C, De Paolis P, Rubattu S, Panina G, Volpe M. Role of angiotensin II AT1 and AT2 subtype receptors in the regulation of atrial natriuretic peptide expression in salt-restricted rats. Basic Res Cardiol 2000; 95:64-69.
137. Takekoshi K, Ishii K, Shibuya S, Kawakami Y, Isobe K, Nakai T. Angiotensin II type 2 receptor counterregulates type 1 receptor in catecholamine synthesis in cultured porcine adrenal medullary chromaffin cells. Hypertension 2002; 39:142-148.
138. Haywood GA, Gullestad L, Katsuya T, Hutchinson HG, Pratt RE, Horiuchi M, Fowler MB. AT1 and AT2 angiotensin receptor gene expression in human heart failure. Circulation 1997; 95:1201-1206.
139. Meggs LG, Coupet J, Huang H, Cheng W, Li P, Capasso JM, et al. Regulation of angiotensin II receptors on ventricular myocytes after myocardial infarction in rats. Circ Res 1993; 72:1149-1162.
140. Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. J Clin Invest 1995; 95:46-54.
141. Lefroy DC, Wharton J, Crake T, Knonk GA, Rutherford RA, Suzuki T, et al. Regional changes in angiotensin II receptor density after experimental myocardial infarction. J Mol Cell Cardiol 1996; 28:429-440.
142. Rogg H, de Gasparo M, Graedel E, Stulz P, Burkart F, Eberhard M, Erne P. Angiotensin II-receptor subtypes in human atria and evidence for alterations in patients with cardiac dysfunction. Eur Heart J 1996; 17:1112-1120.
143. Wharton J, Morgan K, Rutherford RA, Catravas JD, Chester A, Whitehead BF, et al. Differential distribution of angiotensin AT2 receptors in the normal and failing human heart. J Pharmacol Exp Ther 1998; 284:323-336.
144. Henrion D, Kubis N, Levy BI. Physiological and pathophysiological functions of the AT2 subtype receptor of angiotensin II: from large arteries to the microcirculation. Hypertension 2001; 38:1150-1157.
145. Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, et al. Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995; 377:748-750.
146. Akishita M, Yamada H, Dzau VJ, Horiuchi M. Increased vasoconstrictor response of the mouse lacking the angiotensin II type 2 receptor. Biochem Biophys Res Comm 1999; 261:345-349.
147. Abadir PM, Carey RM, Siragy HM. Angiotensin AT2 receptor directly stimulates renal production of nitric oxide in conscious B2-null mice [Abstract]. Hypertension 2002; 40:383.
148. Masaki H, Kurihara T, Yamaki A, Inomata N, Nozawa Y, Mori Y, et al. Cardiac-specific overexpression of angiotenin II AT2 receptor causes attenuated response to AT1 receptor-mediated, pressor and chronotropic effects. J Clin Invest 1998; 101:527-535.
149. 2 receptor in a renal wrap hypertension model. Hypertension 1999; 33:1237-1242.
150. Savoia C, Cosentino F, Maffei A, Spinsanti P, De Paolis P, Francia P, et al. AT2-mediated and NO-dependent vasorelaxation by angiotensin II in SHR treated with losartan [Abstract]. Eur Heart J 2002; 23:362.
151. 1 receptor antagonist in hypertensive rats. Hypertension 1999; 34:1112-1116.
152. Tamura M, Takagi T, Howard EF, Landon EJ, Steimle A, Tanner M, Myers PR. Induction of angiotensin II subtype-2 receptor-mediated blood pressure regulation in synthetic diet-fed rat. J Hypertens 2000; 18:1239-1246.
153. Widdop RE, Matrougui K, Levy BI, Henrion D. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40:516-520.
154. Li Z, Iwai M, Wu L, Shiuchi T, Jinno T, Cui TX, Horiuchi M. Role of AT2 receptor in the brain in regulation of blood pressure and water intake. Am J Physiol 2003; 284:H116-H121.
155. Gigante B, Piras O, De Paolis P, Porcellini A, Natale A, Volpe M. Role of the angiotensin II AT2-subtype receptors the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998; 16: 2039-2043.
156. Dai WJ, Funk A, Herdegen T, Unger T, Culman J. Blockade of central angiotensin AT1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30:2391-2399.
157. Li JS, Touyz RM, Schiffrin EL. Effects of AT1 and AT2 angiotensin
158. Zelezna B, Veselsky L, Velek J, Debeseva Z, Zicha J, Kunes J. Influence of active immunization agonist angiotensin AT1 or AT2 receptor on hypertension development in young and adult SHR. Physiol Res 1999; 48:259-265.
159. Schuijt MP, de Vries R, Saxena PR, Danser AHJ. No vasoactive role of the angiotensin II type 2 receptor in normotensive Wistar rats. J Hypertens 1999; 17:1879-1884.
160. - symporter in the rat heart after myocardial infarction. J Am Cell Cardiol 2001; 37:2154-2165.
161. Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355:1582-1587.
162. Cohn JN, Tognoni G. A randomised trial of the angiotensin receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345:1667-1675.
163. Dickstein K, Kjekshus J. Effect of losartan and captopril on mortality and morbidity in high risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin IJ antagonist losartan. Lancet 2002; 360:752-760.
164. Schneider MD, Lorell BH. AT2, judgement day: which angiotensin receptor is the culprit in cardiac hypertrophy? Circulation 2001; 104:247-248.
165. Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res 2001; 88:654-658.
166. Volpe M, Savoia C, De Paolis P, Ostrowska B, Tarasi D, Rubattu S. The renin-angiotensin system as a risk factor and therapeutic target for cardiovascular and renal disease. J Am Soc Nephrol 2002; 13: S173-S178.